AAA's cancer candidate Lutathera starts PhIII
This article was originally published in Scrip
French diagnostic/therapeutic company Advanced Accelerator Applications (AAA) has pushed its investigational cancer candidate Lutathera (177Lu-DOTA-Octreotate) into Phase III trials, after earlier clinical work suggesting that the drug can extend life expectancy by 3.5 years in a subset of gastro-entero pancreatic neuroendocrine tumour types.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.